Skip to main content
OpenTrials
Completed

NCT Number: NCT07289698

Handgrip Strength Increases the Pressure in the Portal and Left Gastric Veins in Cirrhotic Patients

1.Background Handgrip strength , a core indicator of muscle function, has been confirmed to be significantly associated with the clinical prognosis of patients with liver cirrhosis. However, no studies have explored its correlation with portal venous hemodynamics. 2. Objective The purpose of the study is to examine the effects of Handgrip strength on portal vein and left gastric vein pressure, blood flow velocity and direction in patients with liver cirrhosis.

3. Method: observational study. Detection Timing: Doppler ultrasound was employed to determine the portal flow velocity and direction at baseline and during the handgrip strength test in cirrhotic patients with a history of variceal bleeding. Three days later, prior to TIPS placement, the pressures in the portal pressure and gastric vein pressure were measured both before and after handgrip strength. Furthermore, carvedilol and vasoactive drugs were discontinued three days before the study commenced. 4. Elaboration of the Research Hypothesis 4.1. Core Hypothesis The handgrip strength level in patients with liver cirrhosis is correlated with portal venous system hemodynamic indices. Specifically, enhanced handgrip strength may affect portal hypertension and the hemodynamics of varicose veins by improving systemic muscle function or circulatory status. 4.2. Speculation on potential mechanisms Association between muscle function and circulation: As a representative of systemic muscle function, increased handgrip strength may reflect an increase in cardiac output or changes in splanchnic vascular resistance, thereby influencing portal venous hemodynamics.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • adult patients (≥18 years of age) with cirrhosis and a history of variceal bleeding, who were preparing for TIPS creation for secondary prophylaxis against variceal bleeding

Exclusion criteria

  • Severe congestive heart failure, or severe untreated valvular heart disease
  • Moderate to severe pulmonary hypertension
  • Uncontrolled systemic infection
  • Lesions (e.g., cysts) or tumors in the liver parenchyma that preclude TIPS creation
  • Overt hepatic encephalopathy
  • Unrelieved biliary obstruction
  • Child-Pugh score > 13
  • Model for end-stage liver disease (MELD) score > 18
  • International normalized ratio (INR) > 5
  • Platelet count < 20×109/mm3
  • Participants who had undergone hand or wrist surgery within the previous 3 months or were unable to hold the dynamometer with the testing hand were excluded from the study.

Treatment and study plan

Handgrip strength

Device

Jamar Hand Dynamometer, from Illinois, USA. Maximum handgrip strength was measured three times, with each measurement lasting 3 seconds and a 1-minute interval between tests

Primary outcomes

  1. portal pressure

    Time frame: through study completion, an average of 5 minutes

    Prior to TIPS, the pressure monitoring catheter was connected to the pressure-measuring device. Subsequently, the pressures in both the portal vein and left gastric vein were measured simultaneously at baseline and during the handgrip strength test.

  2. left gastric vein pressure

    Time frame: through study completion, an average of 5 minutes

    Prior to TIPS, the pressure monitoring catheter was connected to the pressure-measuring device. Subsequently, the pressures in both the portal vein and left gastric vein were measured simultaneously at baseline and during the handgrip strength test.

  3. portal flow velocity

    Time frame: At least 72 hours after the baseline handgrip strength and during the handgrip strength phase, measurements were conducted at intervals of 15 seconds, 30 seconds, 45 seconds, and 60 seconds after the release of strength related to the handgrip Strength

  4. Portal vein blood flow direction

    Time frame: At least 72 hours after the baseline handgrip strength and during the handgrip strength phase, measurements were conducted at intervals of 15 seconds, 30 seconds, 45 seconds, and 60 seconds after the release of strength related to the handgrip Strength

Secondary outcomes

  1. Serum albumin (g / l)

    Time frame: Baseline

    Pre-TIPS baseline characteristics ,date (n=32)

  2. alanine aminotransferase(IU / L)

    Time frame: Baseline

    Pre-TIPS baseline characteristics, date (n=32)

  3. aspartate aminotransferase (IU / L)

    Time frame: Baseline

    Pre-TIPS baseline characteristics ,date (n=32)

  4. Total bilirubin (µmol / l)

    Time frame: Baseline

    Pre-TIPS baseline characteristics ,date (n=32)

  5. Prothrombin time (second)

    Time frame: Baseline

    Pre-TIPS baseline characteristics ,date (n=32)

  6. Fasting blood glucose (mmol / l)

    Time frame: Baseline

    Pre-TIPS baseline characteristics ,date (n=32)

  7. triglyceride (mmol / l)

    Time frame: Baseline

    Pre-TIPS baseline characteristics ,date (n=32)

  8. Total cholesterol (mmol / l)

    Time frame: Baseline

    Pre-TIPS baseline characteristics ,date (n=32)

  9. Serum creatinine (µmol / l)

    Time frame: Baseline

    Pre-TIPS baseline characteristics ,date (n=32)

  10. Serum potassium (mmol / l)

    Time frame: Baseline

    Pre-TIPS baseline characteristics ,date (n=32)

  11. Serum sodium (mmol / l)

    Time frame: Baseline

    Pre-TIPS baseline characteristics ,date (n=32)

  12. Serum chloride (mmol / l)

    Time frame: Baseline

    Pre-TIPS baseline characteristics ,date (n=32)

  13. Platelet count (× 109 / mm3)

    Time frame: Baseline

    Pre-TIPS baseline characteristics ,date (n=32)

  14. height

    Time frame: Baseline

  15. weight

    Time frame: Baseline

  16. Model for end-stage liver disease score

    Time frame: Baseline

    Model for end-stage liver disease score: 6-40, the higher scores mean a worse outcome.

  17. Child-Pugh score

    Time frame: Baseline

    Child-Pugh score: 5-15, the higher scores mean a worse outcome

  18. Esophageal varices before endoscopic treatment

    Time frame: Baseline

    The diagnosis of esophageal varices and variceal bleeding in patients is confirmed by upper gastrointestinal endoscopy.

  19. Collateral vessels before TIPS placement

    Time frame: Baseline

    Vascular angiography was performed prior to TIPS placement to diagnose collateral circulation. date (n=32)

  20. Ascites

    Time frame: Baseline

    Prior to TIPS, ascites was evaluated by ultrasound in 32 patients with liver cirrhosis.

  21. Prior overt hepatic encephalopathy

    Time frame: Baseline

  22. Etiology of cirrhosis

    Time frame: Baseline

  23. Age

    Time frame: Baseline

  24. Sex

    Time frame: Baseline

  25. Handgrip Strength

    Time frame: Baseline

Sponsors and collaborators

Lead sponsor

Shanxi Provincial People's Hospital

Other Gov

Collaborators

  • The First Affiliated Hospital of Henan University of Science and Technology

Registry information

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Dec 17, 2025
Registry last updated
Apr 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.